The purpose of this study is to look at a new cell therapy, MT-401, and determine the best dose for treating AML. The study will also look at the safety, tolerability, and effectiveness of this new therapy.
Thank you for your interest, but this study is not currently enrolling.
North Carolina (Statewide)
Clinical or Medical
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.